InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study

BRISBANE, Calif., May 25, 2011 /PRNewswire/ — InterMune (NASDAQ:ITMN – News) will outline the company’s corporate strategy and vision for 2015, including an update on its ongoing plans to commercialize Esbriet® (pirfenidone) in Europe, as well as details on ASCEND, a new Phase 3 pirfenidone study, during a meeting with analysts in New York tomorrow, May 26. InterMune will conduct a live webcast of the presentations beginning at 8:30 a.m. EDT.

2 Responses to InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study

Heya im for the first time here. I discovered this board and I to uncover It truly helpful &amp it helped me out a whole lot. I hope to supply something back and aid other people such as you helped me. afbckdgedkfk

I feel that is among the so much significant information for me. And i’m glad studying your article. However should observation on few general issues, The website taste is ideal, the articles is in point of fact excellent D. Just right activity, cheers dceeaebddefg